Companies in #Multiple Myeloma
Found 4 companies operating in this sector.
Karyopharm Therapeutics is a Newton, Massachusetts-based commercial-stage pharmaceutical company developing and commercializing novel therapies for cancer and other diseases, with its lead asset XPOVIO (selinexor), an oral selective inhibitor of nuclear export (SINE) compound approved by the FDA for multiple oncology indications including multiple myeloma, endometrial cancer, and diffuse large B-cell lymphoma. The company is also advancing selinexor in myelofibrosis through its XPORT-MF-034 Phase 3 trial and exploring next-generation SINE compounds. In May 2026 stockholders approved an amendment to the 2022 Equity Incentive Plan (3.0M new shares added; Form 8-K May 21, 2026), and on July 13, 2026 the Board implemented a 2026 Leadership Cash & Equity Retention Program covering all named executive officers and the CFO using performance-based restricted stock units with a market-cap vesting hurdle (Form 8-K July 17, 2026, accession 0001193125-26-307964).
Legend Biotech is a global clinical-stage biopharmaceutical company pioneering the development of chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and solid tumors. Its lead product, CARVYKTI® (ciltacabtagene autoleucel), is approved for relapsed/refractory multiple myeloma and is co-developed with Johnson & Johnson.
Oncolytics Biotech is a clinical-stage immuno-oncology company developing pelareorep, a systemically delivered oncolytic reovirus, for solid tumors and hematologic malignancies. The company's lead program is in hormone-receptor-positive / HER2-negative breast cancer with ongoing pivotal trial preparations; pelareorep has shown clinical activity in multiple tumor types in combination with checkpoint inhibitors and chemotherapy. Oncolytics reported a corporate restructuring and auditor change in July 2026 (disengaging Ernst & Young and engaging Baker Tilly as the company's independent registered public accounting firm for the 2026 fiscal year, with prior reports containing a going-concern explanatory paragraph). The company is headquartered in San Diego, California and Calgary, Alberta, and trades on the Nasdaq Capital Market under the symbol ONCY.
Tempest Therapeutics is a clinical-stage biotechnology company developing targeted and immune-mediated small-molecule and in vivo CAR-T therapeutics for cancer and autoimmune disease. Its lead candidate, amezalpat (TPST-1120), is an oral selective antagonist of peroxisome proliferator-activated receptor alpha (PPARα) that has completed a Phase 2 trial in first-line unresectable or metastatic hepatocellular carcinoma and is advancing into a pivotal Phase 3 study in combination with atezolizumab and bevacizumab, with Roche supplying atezolizumab and Tempest sponsoring the trial. The pipeline also includes TPST-1495, a dual EP2/EP4 prostaglandin E2 receptor antagonist, and TPST-4003, a CD7-targeted mRNA/LNP in vivo CAR-T candidate. In September 2026 the company signed an exclusive option agreement with Hebei Senlang Biotechnology covering a clinical-stage CD7-targeted lentiviral in vivo CAR-T platform and an associated multiple myeloma Phase 1 asset, following a July 2026 investigator-initiated-trial collaboration between the two companies.